Phase 3 Clinical Announcements Carry 63.6% High Momentum Against 9.4% at Preclinical Stage and 20.0% at Approval While 73 of 205 State No Stage

InnoDexis has published its latest Innovation Intelligence Report covering the clinical pipeline, analyzing 205 corporate clinical announcements across 9 therapeutic areas and 8 modalities and 365 research clinical-evidence records, including 69 randomised trials, during the 1–29 September 2026 observation window. The report reveals that Phase 3 is where the pipeline earns attention and rare disease is where companies lead science: 63.6 percent of Phase 3 announcements carry High momentum, against 9.4 percent at preclinical and IND stage, and companies announce 18 rare and genetic disease records against 8 from research.

Key Findings

Momentum rises with stage to Phase 3. Phase 3 announcements carry High momentum 63.6 percent of the time and score 7.14, against 25.0 percent for Phase 1 and Phase 2, 20.0 percent for approvals and 9.4 percent for preclinical and IND, because approvals are anticipated and Phase 3 is where uncertainty resolves.

Stage is often unstated. Seventy-three of 205 clinical announcements state no stage and score 5.75, so stage-less announcements carry less weight, while named Phase 3 events include Lilly’s Inluriyo approval data and Ondine Biomedical’s 40 percent reduction in surgical-site infections.

Research evidence leads in common diseases. Oncology has 79 research records against 38 corporate, metabolic and obesity 58 against 11, cardiovascular 53 against 12, respiratory 40 against 6 and neurology and psychiatry 34 against 8, while rare and genetic disease reverses at 8 against 18 and immunology and dermatology at 6 against 10.

Asian originators supply licences. Hengrui licensed an oral GLP-1/GIP asset to Novo Nordisk for $300 million upfront and up to $2.6 billion, Boomray licensed a radioligand to Novartis, and Nutshell, IASO, CorrectSequence and Argo Biopharma advanced INDs, CAR-T, base-editing and siRNA data, while AbbVie’s $10.9 billion Apogee acquisition was the largest clinical-asset transaction.

Modality is broad and catalysts are dated. Small molecules lead at 38, then devices and diagnostics at 34, RNA and oligonucleotides at 33, antibodies and biologics at 30 and cell and gene therapy at 25, with Alexion’s efzimfotase alfa PDUFA decision in the first half of 2027 and PTC’s ST-920 BLA submission in Q4 2026.

Strategic Insight and Trend Analysis

The defining structural finding is that attention follows stage, and that the order of evidence reverses by disease type. In the large therapeutic areas congress trials and registries report first, with research evidence outnumbering corporate announcements two to seven times, while in rare and genetic disease gene-therapy approvals, manufacturing and designations, such as FAYUVI, WASKYRA, Andelyn Biosciences, PTC’s ST-920 and the ML4 gene-therapy IND, are announced by companies and foundations ahead of academic publications. Of 205 clinical announcements, 163 are US-headquartered and 20 Chinese.

Platform modalities are maturing. RNA, cell and gene and antibody records are well represented with durable data, including REGENXBIO’s three-year absence of intraocular inflammation, CorrectSequence’s haemoglobin rise from 7.7 to 12.9 g/dL, IASO’s real-world 12-month PFS of 71.5 percent, Argo’s 94 percent plasma PKK reduction and Andelyn’s 500 or more cGMP batches. Clover’s RSV, hMPV and PIV3 combination vaccine shows about 62 percent reduction. Manufacturing capacity constrains gene and cell therapy, which is why Andelyn and KFSH announce capacity.

Cooperative groups and congresses supply the comparators. IASLC, ESC, NRG Oncology and SWOG produce research evidence that companies later use, and much of it lacks a commercial sponsor. The Phase 3 sample is only 22 and momentum is analyst-assigned, and research counts include cohorts and congress abstracts that are not drug trials, so the findings are indicative.

Global and Industry Implications

For corporates and R&D teams, pharma and biotech business development should license or partner on academic outcome evidence, including IASLC cooperative-group results, ESC’s SINGLE-AF with its 69 percent event reduction and Mayo Clinic’s radiosurgery trial, and screen Asian-originated assets such as Hengrui, Boomray, Nutshell, IASO and CorrectSequence. Congress late-breakers and HKEX filings are the named monitoring sources.

For investors and capital allocators, dated catalysts are the investable events: Alexion’s efzimfotase alfa PDUFA decision in the first half of 2027, PTC’s ST-920 BLA in Q4 2026, Cambium Bio’s Phase 3 start in Q4 2026 and Eloxx’s Phase 2b readout in mid-2027. Due diligence should confirm stage, since 73 announcements omit it, and check whether a licence is regional or global. Startups should plan financing around data events, since IND and first-in-human milestones carry 9.4 percent High momentum.

For policymakers and national innovation bodies, evidence from cooperative groups often lacks a sponsor, so funding pragmatic trials in common diseases and supporting gene and cell therapy manufacturing capacity are the named priorities. Reimbursement decisions can draw on SINGLE-AF, CorCal and semaglutide safety data.

InnoDexis Statement

“Phase 3 is where the pipeline earns attention and rare disease is where companies lead science — 63.6 percent of Phase 3 announcements carry High momentum, against 9.4 percent at preclinical and IND stage,” noted InnoDexis in its latest intelligence report.

Conclusion

Because momentum is analyst-assigned, the Phase 3 sample is 22, development stage is unstated in 73 of 205 announcements, the corporate stream is 61.5 percent US-headquartered and one month supports no trend, the findings are cross-sectional. The signals to watch are whether a second Phase 3 of a generative-AI-designed drug is registered, whether efzimfotase alfa and ST-920 reach decision and review milestones, whether Hengrui’s HRS-1596 enters a Novo Nordisk trial, and whether an academic RCT result is licensed to industry. The complete Clinical Pipeline Tracker September 2026 is available to InnoDexis subscribers and enterprise clients.

About InnoDexis

InnoDexis is a real-time innovation intelligence platform connecting scientific discovery to commercial opportunity. Powered by InnoGraph, its proprietary innovation knowledge graph, the platform maps technologies across the entire lifecycle, from early-stage research (TRL 1) to market deployment (TRL 9), connecting researchers, institutions, startups, companies, products and emerging opportunities.

Covering 40+ specialised industry segments and 360 technology areas, InnoDexis delivers innovation tracking, research discovery, product and startup intelligence, investment insights, and AI-powered reports. Its mission is to bridge the gap between scientific discovery and real-world impact.

InnoDexis — From Lab to Market: Real-Time Innovation Intelligence.